Stock Events

Stock Events

Lexicon Pharmaceuticals 

$1.59
177
-$0.01-0.31% Today

Statistics

Day High
1.61
Day Low
1.55
52W High
1.83
52W Low
0.45
Volume
562,220
Avg. Volume
2,978,383
Mkt Cap
575.99M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30AprExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.18
-0.12
-0.05
0.01
Expected EPS
-0.03445
Actual EPS
N/A

Financials

-644.78%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
62.16MRevenue
-400.81MNet Income

Analyst Ratings

$4.15Average Price Target
The highest estimate is 6.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LXRX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious diseases, including cystic fibrosis, where there is some overlap in therapeutic areas with Lexicon.
AMGEN
AMGN
Mkt Cap187.56B
Amgen competes in the biopharmaceutical space, developing drugs that could potentially be in direct competition with Lexicon's pipeline, especially in areas like cardiovascular diseases.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences is involved in the discovery, development, and commercialization of innovative therapeutics in areas overlapping with Lexicon's interests, such as liver disease.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals is known for its innovation in biotechnology, competing with Lexicon in developing drugs for conditions like diabetes and cardiovascular diseases.
Biogen
BIIB
Mkt Cap26.03B
Biogen competes with Lexicon in the biopharmaceutical field, focusing on developing therapies for neurological and neurodegenerative diseases, a potential area of interest for Lexicon.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie operates in similar therapeutic areas as Lexicon, including immunology and oncology, making it a direct competitor in the pharmaceutical market.
Merck
MRK
Mkt Cap298.84B
Merck & Co. is a global healthcare company that competes with Lexicon through its broad range of prescription medicines, vaccines, biologic therapies, and animal health products.
Pfizer
PFE
Mkt Cap161.09B
Pfizer is a direct competitor due to its extensive range of healthcare products that could compete with Lexicon's drug pipeline in various therapeutic areas.
Novartis
NVS
Mkt Cap297.32B
Novartis competes with Lexicon in the pharmaceutical and biotechnology industry, focusing on a wide range of therapeutic areas, including those targeted by Lexicon.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca is a global, science-led biopharmaceutical business that competes with Lexicon in developing innovative medicines in oncology, cardiovascular, renal & metabolism, and respiratory diseases.

About

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Show more...
CEO
Dr. Michael S. Exton Ph.D.
Employees
103
Country
US
ISIN
US5288723027

Listings

XNAS
US
LXRX
BOATS
BOATS
LXRX.BOATS

0 Comments

Share your thoughts

FAQ

What is Lexicon Pharmaceuticals stock price today?▼
The current price of LXRX is $1.59 USD — it has decreased by -0.31% in the past 24 hours. Watch Lexicon Pharmaceuticals stock price performance more closely on the chart.
What is Lexicon Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Lexicon Pharmaceuticals stocks are traded under the ticker LXRX.
Is Lexicon Pharmaceuticals stock price growing?▼
LXRX stock has risen by +1.28% compared to the previous week, the month change is a -7.6% fall, over the last year Lexicon Pharmaceuticals has showed a +205.37% increase.
What is Lexicon Pharmaceuticals market cap?▼
Today Lexicon Pharmaceuticals has the market capitalization of 575.99M
When is the next Lexicon Pharmaceuticals earnings date?▼
Lexicon Pharmaceuticals is going to release the next earnings report on April 30, 2026.
What were Lexicon Pharmaceuticals earnings last quarter?▼
LXRX earnings for the last quarter are -0.04 USD per share, whereas the estimation was -0.07 USD resulting in a +42.01% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Lexicon Pharmaceuticals revenue for the last year?▼
Lexicon Pharmaceuticals revenue for the last year amounts to 62.16M USD.
What is Lexicon Pharmaceuticals net income for the last year?▼
LXRX net income for the last year is -400.81M USD.
How many employees does Lexicon Pharmaceuticals have?▼
As of April 07, 2026, the company has 103 employees.
In which sector is Lexicon Pharmaceuticals located?▼
Lexicon Pharmaceuticals operates in the Health Care sector.
When did Lexicon Pharmaceuticals complete a stock split?▼
The last stock split for Lexicon Pharmaceuticals was on May 21, 2015 with a ratio of 1:7.
Where is Lexicon Pharmaceuticals headquartered?▼
Lexicon Pharmaceuticals is headquartered in The Woodlands, US.